Revance Therapeutics (RVNC) Expands into US Market with the Launch of DAXXIFY

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to Revance Therapeutics (RVNC) Expands into US Market with the Launch of DAXXIFY

Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia

May 9, 2024 4:05 PM EDT

DAXXIFY® for the treatment of cervical dystonia is the first and only peptide-formulated, long-lasting neurotoxin that offers the potential to improve duration of symptom control1 Revance has received a Permanent J-Code and has already secured coverage for 78% of commercial lives with top health plans, while also launching patient affordability programs Todays launch provides first entry into the $2.7 billion U.S. therapeutic neurotoxin market with a new and compelling treatment option2

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced the commercial... More